Please login to the form below
situximab
This page shows the latest situximab news and features for those working in and with pharma, biotech and healthcare.
EMA backs Janssen rare disease drug for approval
Castleman's disease treatment Sylvant wins CHMP recommendation. J&J subsidiary Janssen-Cilag's Castleman's disease treatment Sylvant (situximab) has been recommended for approval in Europe.
Latest news
-
Boehringer/Lilly's empagliflozin among CHMP recommendations
There were also recommendations for four orphan drugs: Janssen-Cilag's Sylvant (situximab) and, along with the companion diagnostic drugs Folcepri (etarfolatide) and Neocepri (folic acid), Endocyte's Vynfinit (vintafolide).
More from news
Approximately 1 fully matching, plus 1 partially matching documents found.
Featured jobs
- Account Manager – Healthcare advertising
-
Salary TBC
-
Account Director – UK Office
-
Excellent salary and benefits
Subscribe to our email news alerts
PMHub
Clark Health Communications
Clark Health Communications (CHC) is an independent, award-winning health and medical communications agency. Our collaboration with experts and advocates enhances...
Latest intelligence
- Article: Like, Like, Like: Harnessing the power of social media insights
- ...
- Its Know Your Numbers week
- Do you know yours?...
- What is changing in mental health and dementia care?
- Paul Midgley, of Wilmington Healthcare, takes a look at the NHS Long Term Plan's bid to transform mental health and dementia services...
Quick links
Infographics
